Dossier assessment
Insulin glargine/lixisenatide (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Insulin glargine/lixisenatide (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Insulin glargine/lixisenatide (type 2 diabetes mellitus) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Adults with type 2 diabetes mellitus when metformin combined with another oral glucose-lowering medicinal product or with basal insulin does not provide adequate glycaemic control
Depending on therapeutic indication and treatment goal: hint of lesser benefit than under the comparator therapy or added benefit not proven
Additional information
Federal Joint Committee (G-BA)
2019-07-04 A G-BA decision was published.
Project details
- Project no.
- A18-16
- Commission
- Commission awarded on 28.02.2018 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Digestion, metabolism and hormones
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
Connected Projects
-
Dossier assessment
Insulin glargine/lixisenatide (type 2 diabetes mellitus) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed